tirzepatide thyroid cancer risk and nodules: what the research actually shows about safety Black Box Warning of Tirzepatide

At Omada Health, we have designed that model with purpose

Edit, sign, and share cvs caremark appeal form online

Weight loss injections in Fort Lauderdale, FL with telehealth at Florida Bariatric and Plastic Surgery MD

It has great support and shipping but pharmacy issues and weird pricing.

New study published this week in JAMA Network Open (Tatum et al) looked at GLP-1 medications in patients with breast cancer and their impact on overall survival (death from any cause) and...

Study Snapshot Design: Randomized, double-blind, placebo-controlled trial Duration: 26 weeks Population: Treatment-seeking adults with AUD + obesity Completers: 88 participants Intervention: Once-weekly semaglutide + behavioral therapy Funding: Novo Nordisk Foundation Key Findings (Simplified) Heavy drinking days significantly reduced ~41% reduction with semaglutide vs ~26% placebo Treatment effect difference: ~13.7% improvement vs placebo Absolute reduction: ~12 fewer heavy drinking days/month (vs ~8 days in placebo) Alcohol-Related Outcomes Total alcohol intake Frequency of binge/heavy drinking episodes Alcohol craving (supported by prior trials) Biomarker-confirmed reductions in alcohol exposure Metabolic & Somatic Benefits Significant weight loss Improved blood pressure & cardiometabolic profile Reinforces dual benefit: metabolic + behavioral modulation Mechanistic Insight (Emerging) GLP-1 receptor agonists may: Modulate reward pathways Reduce dopamine-driven craving signals Decrease cue-induced alcohol seeking behavior Important Limitations Small sample size (n=88 completers) Conducted in motivated, treatment-seeking population Combined with cognitive behavioral therapy (not drug-only effect) No long-term post-treatment follow-up Why This Matters AUD remains under-treated globally Current pharmacotherapies have limited uptake & modest efficacy Semaglutide introduces a novel, biologically plausible pathway Potential shift toward metabo-psychiatric therapeutics Clinical Takeaway This is not just a weight-loss drug anymore It may represent a new frontier in addiction medicine But: Larger, real-world trials are essential before routine clinical adoption